Previous studies in humans demonstrated that events that lead to the inhibition of the p53/Rb pathways occurred at early stages of the disease, indicating that these tumor suppressor pathways might play a critical role in preventing liver cancer initiation [19]. This evidence concerns the gene RB1 and neoplasm.